{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/agility-and-flexibility-are-key-delivering-tandem-mega-oncology-trials-highly-complex#webpage",
"url": "https://www.fortrea.com/insights/agility-and-flexibility-are-key-delivering-tandem-mega-oncology-trials-highly-complex",
"name": "Agility and flexibility are key in delivering tandem mega oncology trials in a highly complex clinical trial landscape",
"description": "Explore this Fortrea Case Study showcasing how an innovative hybrid delivery model enabled the successful execution of two simultaneous Phase III oncology mega trials in a highly complex global clinical research environment. Supporting a large pharmaceutical sponsor developing a breast cancer therapy, Fortrea provided operational leadership across studies spanning more than 45 countries, 1,400 sites, over 10,000 study participants, and a planned duration of 15 years. The case study highlights how Fortrea collaborated with sponsor affiliates and Academic Research Organizations (AROs) to create a unified global delivery framework that leveraged common tools, systems, processes, and governance structures while maintaining operational consistency across diverse regions. Key focus areas included leading global feasibility and site selection activities, managing a complex network of global, regional, and local vendors, coordinating study startup activities, supporting regulatory submissions, and driving efficient execution across large-scale multinational oncology studies. The resource demonstrates how agility, flexibility, and strong operational oversight helped navigate an increasingly competitive oncology landscape while supporting study objectives, enrollment planning, site performance, and long-term program success. Through strategic collaboration, scalable infrastructure, and deep oncology expertise, Fortrea helped establish a robust global clinical trial ecosystem capable of supporting some of the largest and most complex oncology development programs"
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Agility and flexibility are key in delivering tandem mega oncology trials in a highly complex clinical trial landscape",
"item": "https://www.fortrea.com/insights/agility-and-flexibility-are-key-delivering-tandem-mega-oncology-trials-highly-complex"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/agility-and-flexibility-are-key-delivering-tandem-mega-oncology-trials-highly-complex#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/agility-and-flexibility-are-key-delivering-tandem-mega-oncology-trials-highly-complex#webpage"
},
"headline": "Hybrid Delivery and Global Feasibility for Oncology Mega Trials | Fortrea Case Study",
"description": "Explore this Fortrea Case Study showcasing how an innovative hybrid delivery model enabled the successful execution of two simultaneous Phase III oncology mega trials in a highly complex global clinical research environment. Supporting a large pharmaceutical sponsor developing a breast cancer therapy, Fortrea provided operational leadership across studies spanning more than 45 countries, 1,400 sites, over 10,000 study participants, and a planned duration of 15 years. The case study highlights how Fortrea collaborated with sponsor affiliates and Academic Research Organizations (AROs) to create a unified global delivery framework that leveraged common tools, systems, processes, and governance structures while maintaining operational consistency across diverse regions. Key focus areas included leading global feasibility and site selection activities, managing a complex network of global, regional, and local vendors, coordinating study startup activities, supporting regulatory submissions, and driving efficient execution across large-scale multinational oncology studies. The resource demonstrates how agility, flexibility, and strong operational oversight helped navigate an increasingly competitive oncology landscape while supporting study objectives, enrollment planning, site performance, and long-term program success. Through strategic collaboration, scalable infrastructure, and deep oncology expertise, Fortrea helped establish a robust global clinical trial ecosystem capable of supporting some of the largest and most complex oncology development programs",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-14",
"dateModified": "2026-04-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/oncology-mega-trials.pdf",
"encodingFormat": "application/pdf"
}
}
]
}